Topics

"Eos Biosciences, Inc.∨derfield=date∨derval=DESC" News Stories

10:48 EDT 21st July 2019 | BioPortfolio

Here are the most relevant search results for "Eos Biosciences, Inc.∨derfield=date∨derval=DESC" found in our extensive news archives from over 250 global news sources.

More Information about Eos Biosciences, Inc.∨derfield=date∨derval=DESC on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Eos Biosciences, Inc.∨derfield=date∨derval=DESC for you to read. Along with our medical data and news we also list Eos Biosciences, Inc.∨derfield=date∨derval=DESC Clinical Trials, which are updated daily. BioPortfolio also has a large database of Eos Biosciences, Inc.∨derfield=date∨derval=DESC Companies for you to search.

Showing "Biosciences derfield date derval DESC" News Articles 1–25 of 6,000+

Saturday 20th July 2019

Week in Review: Three China Biopharmas Announce Plans for Shanghai/Hong Kong IPOs

Deals and Financings • HitGen of Chengdu, a small molecule discovery CRO with over 60 partnerships, was approved for a $97 million IPO on Shanghai's new STAR Exchange; • Shenzhen Chipscreen Biosciences, a profitable company, will IPO on Shanghai's STAR Board to advance its portfolio of 14 novel small molecules; • Alphamab Oncology, a spinout from Suzhou Alphamab, was stage a Hong Ko...


Pharmstandard Strategic SWOT Analysis Review [Report Updated: 28032019] Prices from USD $125

Pharmstandard Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.This uptotheminute company report will help you to formulate strategies to drive your business by en...

Affymetrix Genechip Hybridization Oven 640 Hybridisierungsofen 70°C P/N 800139

AU $1,404.43End Date: Tuesday Aug-6-2019 20:09:06 ESTBuy It Now for only: AU $1,404.43Buy It Now | Add to watch list Biotech365 : Affymetrix Genechip Hybridization Oven 640 Hybridisierungsofen 70°C P/N 800139 BioMarketplace You want to propose your products or a … Continue reading →


Scientific Industries Vortex Genie 2 Laboratory Test Tube Shaker Mixer

£70.00End Date: Sunday Aug-18-2019 21:00:41 BSTBuy It Now for only: £70.00Buy It Now | Add to watch list Biotech365 : Scientific Industries Vortex Genie 2 Laboratory Test Tube Shaker Mixer BioMarketplace You want to propose your products or a Biotech … Continue reading →

Friday 19th July 2019

Shimadzu Rxi-5ms GC column 30 m 0.25 mmID 0.25 um df

EUR 445.69End Date: Saturday Jul-27-2019 19:45:29 ISTBuy It Now for only: EUR 445.69Buy It Now | Add to watch list Biotech365 : Shimadzu Rxi-5ms GC column 30 m 0.25 mmID 0.25 um df BioMarketplace You want to propose your products … Continue reading →

HP 05061-6070 Accessory Kit for Agilent 5061B Cesium Beam Frequency Standard

$99.95End Date: Sunday Aug-18-2019 23:46:11 PDTBuy It Now for only: $99.95Buy It Now | Add to watch list Biotech365 : HP 05061-6070 Accessory Kit for Agilent 5061B Cesium Beam Frequency Standard BioMarketplace You want to propose your products or a … Continue reading →

BioTek uQuant Absorbance Microplate Reader + Software + Laptop + Warranty

AU $3,830.74End Date: Tuesday Aug-6-2019 10:26:35 ESTBuy It Now for only: AU $3,830.74Buy It Now | Add to watch list Biotech365 : BioTek uQuant Absorbance Microplate Reader + Software + Laptop + Warranty BioMarketplace You want to propose your products … Continue reading →

Amedisys Announces Second Quarter Earnings Release and Conference Call Date

BATON ROUGE, La., July 19, 2019 (GLOBE NEWSWIRE) — Amedisys, Inc. (NASDAQ: AMED), announced today that it will report results for the second quarter ended June 30, 2019, after the market closes on July 31, 2019.  The Company will host … Continue reading →

Theramed Health Corporation Announces Completion of Plan of Arrangement for EGF Health Holdings Corp.

VANCOUVER, BC / ACCESSWIRE / July 19, 2019 / Theramed Health Corporation (CSE: TMED, OTCQB: EVAHF) (the “Company”) is pleased announce to that the plan of arrangement as previously announced March 17, 2017 and July 12, 2019, of its wholly owned subsidiary “EGF HEALTH

Human medicines European public assessment report (EPAR): Renvela, sevelamer carbonate, Hyperphosphatemia,Renal Dialysis, Date of authorisation: 09/06/2009, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Renvela, sevelamer carbonate, Hyperphosphatemia,Renal Dialysis, Date of authorisation: 09/06/2009, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Orencia, abatacept, Arthritis, Psoriatic,Arthritis, Juvenile Rheumatoid,Arthritis, Rheumatoid, Date of authorisation: 21/05/2007, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Orencia, abatacept, Arthritis, Psoriatic,Arthritis, Juvenile Rheumatoid,Arthritis, Rheumatoid, Date of authorisation: 21/05/2007, Revision: 29, Status: Authorised

DionyMed Signs Definitive Agreements With Innovative Industrial Properties to Finance a Southern California Cannabis Campus Acquisition, Expanding DYME’s Direct-to-Consumer and Distribution Platform Statewide

DionyMed Brands Inc. (“DionyMed” or “Company”) (CSE: DYME)(OTCQB:DYMEF), a multi-state cannabis brands platform, announced today that it has signed a definitive agreement to acquire select assets from MM Esperanza 2 LLC, doing business as “MMAC,” and MMAC’s 1.83 acre Los Angeles cannabis campus. This acquisition marks the expansion of DionyMed’s operational capabilities in Souther...

Human medicines European public assessment report (EPAR): Aripiprazole Zentiva, aripiprazole, Schizophrenia,Bipolar Disorder, Date of authorisation: 25/06/2015, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Aripiprazole Zentiva, aripiprazole, Schizophrenia,Bipolar Disorder, Date of authorisation: 25/06/2015, Revision: 6, Status: Authorised

Momenta Pharmaceuticals Announces Date of Second Quarter 2019 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., July 19, 2019 (GLOBE NEWSWIRE) — Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the … Continue reading →

Tandem Diabetes Care to Announce Second Quarter 2019 Financial Results on August 1, 2019

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2019 results after the financial markets close on Thursday, August 1, 2019. The Company will hold a conference call and simultaneous webcast on the same day at 4:30pm Eastern Time (1:30pm Pacific Time), to discuss its second quarter 2019 financial and operatin...

Human medicines European public assessment report (EPAR): Vaborem, meropenem / vaborbactam, Urinary Tract Infections,Bacteremia,Bacterial Infections,Respiratory Tract Infections,Pneumonia,Pneumonia, Ventilator-Associated, Date of authorisation: 20/11/2018

Human medicines European public assessment report (EPAR): Vaborem, meropenem / vaborbactam, Urinary Tract Infections,Bacteremia,Bacterial Infections,Respiratory Tract Infections,Pneumonia,Pneumonia, Ventilator-Associated, Date of authorisation: 20/11/2018, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Abilify, aripiprazole, Schizophrenia,Bipolar Disorder, Date of authorisation: 04/06/2004, Revision: 44, Status: Authorised

Human medicines European public assessment report (EPAR): Abilify, aripiprazole, Schizophrenia,Bipolar Disorder, Date of authorisation: 04/06/2004, Revision: 44, Status: Authorised

July 19 Financial Quick Takes: Amarin raises cash ahead of Vascepa PDUFA date, plus Atara, Sunstone and Forendo

Time-to-Treatment Discontinuation of Therapy in NSCLC Trials

Is therapy start date to date of discontinuation or death a potential efficacy endpoint for real-world evidence trials? Annals of Oncology

Acerus Announces Closing of US$5 Million Secured Term Loan

Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB:ASPCF) today announced that it has entered into a US$5 million subordinated secured term loan facility (“the Loan”) with First Generation Capital Inc. (“First Generation”), a company affiliated with the Chairman of the Board of Directors of Acerus.(1) The Loan is subordinated to the existing US$9 mill...

Human medicines European public assessment report (EPAR): Prolia, denosumab, Bone Resorption,Osteoporosis, Postmenopausal, Date of authorisation: 26/05/2010, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Prolia, denosumab, Bone Resorption,Osteoporosis, Postmenopausal, Date of authorisation: 26/05/2010, Revision: 21, Status: Authorised

Chipscreen Poised to be One of the First IPOs on Shanghai's STAR Exchange

Shenzhen Chipscreen Biosciences is expected to be one of the first IPOs on Shanghai's new STAR Board for young technology companies. STAR IPOs are expected to begin next week. Chipscreen specializes in discovering and developing novel small molecule drugs for needs in oncology, metabolic disease and autoimmune disease. Unlike many STAR IPO companies, Chipscreen is profitable. In 2015, its cancer d...

Aktionäre von McDonalds erhalten seit 1976 eine Dividende

Die amerikanische Schnellrestaurantkette McDonalds Corp. (ISIN: US5801351017, NYSE: MCD) zahlt am 17. September 2019 eine Quartalsdividende von 1,16 US-Dollar an die Aktionäre aus (Record date ist ...

Unser Robot zum Dow: Unverändert, Merck und Exxon je 4 Tage im Plus

Der Dow Jones gewann am Donnerstag 0,01% auf 27222,97 Punkte. Year-to-date liegt der Dow Jones nun 16,7% im Plus. Es gab bisher 77 Gewinntage und 60 Verlusttage. Auf das Jahreshoch fehlen 0,5%, vom...

Thursday 18th July 2019

Agilent expands cell analysis portfolio with BioTek acquisition

Agilent Technologies has signed a definitive agreement to acquire the privately owned BioTek Instruments for $1.165 billion. With anticipated tax benefits for Agilent, the net purchase price is expected to be approximately $1.05 billion. Headquartered in Vermont, USA, BioTek is a designer, manufacturer and distributor of innovative life science instrumentation. Its comprehensive product line incl...


Quick Search

News Quicklinks